{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:42:43Z","timestamp":1792154563656,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014114","name":"GW Research Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014114","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.yebeh.2025.110302","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T15:21:25Z","timestamp":1741706485000},"page":"110302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Real-world experience of cannabidiol in conjunction with clobazam for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome: Results from a retrospective multicentre chart review in Germany"],"prefix":"10.1016","volume":"166","author":[{"given":"Adam","family":"Strzelczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schubert-Bast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"von Podewils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Knake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin Alexandra","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Buhleier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka","family":"Immisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kurlemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2025.110302_b0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/epi4.12319","article-title":"Seizure burden in severe early-life epilepsy: Perspectives from parents","volume":"4","author":"Berg","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2025.110302_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108239","article-title":"The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome","volume":"123","author":"Auvin","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110302_b0015","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3389\/fneur.2017.00712","article-title":"The Burden of Severely Drug-Refractory Epilepsy: A Comparative Longitudinal Evaluation of Mortality, Morbidity, Resource Use, and Cost Using German Health Insurance Data","volume":"8","author":"Strzelczyk","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2025.110302_b0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s42466-022-00186-9","article-title":"Exploring the relationships between composite scores of disease severity, seizure-freedom and quality of life in Dravet syndrome","volume":"4","author":"Strzelczyk","year":"2022","journal-title":"Neurol Res Pract"},{"key":"10.1016\/j.yebeh.2025.110302_b0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/dmcn.13591","article-title":"Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey","volume":"60","author":"Lagae","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2025.110302_b0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","article-title":"A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2025.110302_b0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40263-020-00784-8","article-title":"Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies","volume":"35","author":"Strzelczyk","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2025.110302_b0040","unstructured":"EMA. Epidyolex\u00ae 100 mg\/ml oral solution: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/epidyolex-epar-product-information_en.pdf. 2023. [Accessed January 2025]."},{"key":"10.1016\/j.yebeh.2025.110302_b0045","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/ane.13351","article-title":"Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials","volume":"143","author":"Gunning","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2025.110302_b0050","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ane.13305","article-title":"Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials","volume":"142","author":"Devinsky","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2025.110302_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2019.106263","article-title":"Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam","volume":"160","author":"Savage","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2025.110302_b0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2025.110302_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109159","article-title":"Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex\u00ae (cannabidiol) in patients with refractory epilepsy","volume":"141","author":"Georgieva","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110302_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.673135","article-title":"Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome","volume":"12","author":"Iannone","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2025.110302_b0075","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/epi4.12699","article-title":"Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study","volume":"8","author":"K\u00fchne","year":"2023","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2025.110302_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108958","article-title":"Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy","volume":"137","author":"Villanueva","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110302_b0085","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.seizure.2023.05.003","article-title":"Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome","volume":"110","author":"Nabbout","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110302_b0090","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","author":"von Elm","year":"2007335806","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2025.110302_b0095","unstructured":"Electronic Medicines Compendium. Clobazam. Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/15103\/smpc#gref. 2024. [Accessed January 2025]."},{"key":"10.1016\/j.yebeh.2025.110302_b0100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1474-4422(23)00409-X","article-title":"Corticosteroids versus clobazam for treatment of children with epileptic encephalopathy with spike-wave activation in sleep (RESCUE ESES): a multicentre randomised controlled trial","volume":"23","author":"van Arnhem","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2025.110302_b0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2014.01.025","article-title":"Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy","volume":"51","author":"Klehm","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2025.110302_b0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1756285614521314","article-title":"Experience in the use of clobazam in the treatment of Lennox\u2013Gastaut syndrome","volume":"7","author":"Purcarin","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2025.110302_b0115","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fneur.2020.00829","article-title":"Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study","volume":"11","author":"D'Onofrio","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2025.110302_b0120","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/epi.16936","article-title":"The long-term efficacy of cannabidiol in the treatment of refractory epilepsy","volume":"62","author":"Patel","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110302_b0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pediatrneurol.2023.10.012","article-title":"Real-Life Experience With Purified Cannabidiol Treatment for Refractory Epilepsy: A Multicenter Retrospective Study","volume":"150","author":"Tzadok","year":"2024","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2025.110302_b0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.seizure.2023.07.009","article-title":"Real-world experience with cannabidiol as add-on treatment in drug-resistant epilepsy","volume":"111","author":"Vicino","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110302_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108325","article-title":"Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"124","author":"Anderson","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110302_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107280","article-title":"Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey","volume":"200","author":"Berg","year":"2024","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2025.110302_b0145","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/08830738231185241","article-title":"Caregivers' Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study","volume":"38","author":"Marshall","year":"2023","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2025.110302_b0150","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/epi.17665","article-title":"Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program","volume":"64","author":"Flamini","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110302_b0155","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.seizure.2022.11.006","article-title":"Cannabidiol in refractory status epilepticus: A review of clinical experiences","volume":"103","author":"Duda","year":"2022","journal-title":"Seizure"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025000411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025000411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T08:30:27Z","timestamp":1761640227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505025000411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":31,"alternative-id":["S1525505025000411"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110302","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience of cannabidiol in conjunction with clobazam for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome: Results from a retrospective multicentre chart review in Germany","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110302"}}